Algeta is a focused oncology company developing targeted therapies for patients with cancer based
on its alpha-pharmaceutical platform.

Algeta's lead product based on radium-223 is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced cancer. It is partnered with Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from prostate cancer.